| [Abstract] Objective To evaluate the efficacy and safety of direct antiviral agents (DAA) in patients with HCV recurrence after liver transplantation. Methods The clinical data of 14 patients with HCV recurrence after liver transplantation treated with DAAs in Beijing Youan Hospital, Capital Medical University from February 2011 to December 2018 were retrospectively analyzed. The differences of liver function, renal function, complete blood count, coagulation level, virology level and noninvasive fibrosis score, APRI, between baseline and end of treatment (EOT) were compared. Adverse reaction data was collected by electronic medical record system and/or telephone follow-up. Results Virological clearance were achieved in 14 patients at the EOT, and the sustained virological response rates at 12 weeks and 24 weeks were 100% respectively. There was no virological recurrence during the follow-up period. Comparing with the baseline, ALT, AST, TBIL, γ-glutamyl transpeptadase and APRI decreased significantly at the EOT, while WBC, HGB, PLT, CRE, glomerular filtration rate (GFR) and blood glucose had no significant differences. Adverse reactions were observed in 3 patients during DAA treatment, which were mild and could be relieved naturally. Conclusions DAA treatment for patients with HCV recurrence after liver transplantation is safe and effective. |